局限性胰腺癌的分段治疗:癌症委员会认证与总生存改善相关吗?
基于美国国家癌症数据库2006至2019年接受胰十二指肠切除术或远端胰腺切除术并围术期系统治疗的临床I-III期胰腺癌患者,48.3%存在分段治疗;分段治疗中在非癌症委员会认证机构接受系统治疗者接受新辅助系统治疗的比例更低(27.7% vs 40.1% vs 36.8%,P<.001);Cox分析显示分段治疗与总生存风险无关(校正风险比=0.99,95%CI[0.94-1.06],P=.8),Kaplan-Meier分析各治疗队列5年总生存无显著差异。
要点
- 在11,732例局限性胰腺癌手术患者中,5,668例(48.3%)存在分段治疗,3,426例(29.2%)在非癌症委员会认证机构接受系统治疗。
- 分段治疗非癌症委员会认证组接受新辅助系统治疗的比例低于分段治疗癌症委员会认证组和非分段治疗组(27.7% vs 40.1% vs 36.8%,P<.001)。
- Cox分析显示分段治疗与总生存风险无关(校正风险比=0.99,95%CI[0.94-1.06],P=.8),各治疗队列5年总生存无显著差异。
核心结论
- 在局限性胰腺癌分段治疗患者中,在癌症委员会认证机构接受系统治疗者更可能接受新辅助治疗,但与未分段治疗或在非认证机构接受系统治疗者相比总生存无显著改善。
研究设计与样本
- 查询美国国家癌症数据库,纳入2006年至2019年间接受胰十二指肠切除术和远端胰腺切除术并围术期系统治疗的临床I-III期胰腺癌患者。
- 将系统治疗机构与手术机构不同者定义为分段治疗,并进一步分为分段治疗癌症委员会认证组和分段治疗非癌症委员会认证组。
- 共11,732例患者符合纳入标准,其中5,668例(48.3%)存在分段治疗,3,426例(29.2%)为分段治疗非癌症委员会认证。
主要发现
- 分段治疗非癌症委员会认证组接受新辅助系统治疗的比例低于分段治疗癌症委员会认证组和非分段治疗组(27.7% vs 40.1% vs 36.8%,P<.001)。
- Cox分析显示高龄、合并症、淋巴结阳性疾病和机构类型与总生存风险相关。
- 分段治疗与总生存风险无关(校正风险比=0.99,95%CI[0.94-1.06],P=.8)。
- Kaplan-Meier分析显示各治疗队列5年总生存无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prior studies of fragmentation of care in pancreatic cancer have not adjusted for indicators of hospital quality such as Commission on Cancer accreditation. The effect of fragmentation of care has not been well defined. METHODS: We queried the National Cancer Database to identify patients undergoing pancreaticoduodenectomy and distal pancreatectomy with perioperative systemic therapy for clinical stages I-III pancreatic cancer between 2006 and 2019. Patients who received systemic therapy at a center different than the center performing surgery were categorized as having fragmentation of care. Patients having fragmentation of care were further categorized on the basis of whether (fragmentation of care Commission on Cancer) or not (fragmentation of care non-Commission on Cancer) systemic therapy was administered at a facility accredited by the Commission on Cancer. RESULTS: A total of 11,732 patients met inclusion criteria; 5,668 (48.3%) underwent fragmentation of care, and 3,426 (29.2%) fragmentation of care non-Commission on Cancer. Patients undergoing fragmentation of care non-Commission on Cancer were less likely to receive neoadjuvant systemic therapy than those undergoing fragmentation of care Commission on Cancer or non-fragmented care (27.7% vs 40.1% vs 36.8%, P < .001). On Cox analysis, advanced age, comorbid disease, node-positive disease, and facility type were associated with risk of overall survival. Fragmentation of care was not (adjusted hazard ratio = 0.99, 95% confidence interval [0.94-1.06], P = .8). On Kaplan-Meier analysis, there were no significant differences in 5-year overall survival between treatment cohorts. CONCLUSION: In patients undergoing fragmentation of care for localized pancreatic cancer, those treated with systemic therapy in Commission on Cancer accredited facilities are more likely to be given neoadjuvant therapy but demonstrate no significant improvement in survival relative to those undergoing non-fragmented care or those undergoing fragmentation of care but receiving systemic therapy in nonaccredited facilities.
引用
- Park SS, Verm RA, Abdelsattar ZM, et al. Fragmented care in localized pancreatic cancer: Is commission on cancer accreditation associated with improved overall survival? Surgery. 2023. PMID: 37863686. doi:10.1016/j.surg.2023.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。